RESUMO
The review collects together some recent information on the identity and pharmacological properties of magnoflorine, a quaternary aporphine alkaloid, that is widely distributed within the representatives of several botanical families like Berberidaceae, Magnoliaceae, Papaveraceae, or Menispermaceae. Several findings published in the scientific publications mention its application in the treatment of a wide spectrum of diseases including inflammatory ones, allergies, hypertension, osteoporosis, bacterial, viral and fungal infections, and some civilization diseases like cancer, obesity, diabetes, dementia, or depression. The pharmacokinetics and perspectives on its introduction to therapeutic strategies will also be discussed.
Assuntos
Aporfinas/química , Aporfinas/farmacologia , Descoberta de Drogas , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Animais , Antialérgicos/química , Antialérgicos/farmacocinética , Antialérgicos/farmacologia , Anti-Infecciosos/química , Anti-Infecciosos/farmacocinética , Anti-Infecciosos/farmacologia , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacocinética , Anti-Inflamatórios/farmacologia , Antidepressivos/química , Antidepressivos/farmacocinética , Antidepressivos/farmacologia , Antineoplásicos/química , Antineoplásicos/farmacocinética , Antineoplásicos/farmacologia , Antioxidantes/química , Antioxidantes/farmacocinética , Antioxidantes/farmacologia , Aporfinas/farmacocinética , Metabolismo dos Carboidratos/efeitos dos fármacos , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Extratos Vegetais/farmacocinética , Plantas/químicaRESUMO
ABSTRACT Repirinast is a new, synthetic, disodium cromoglycate-like antiallergic agent for oral administration in humans. This study evaluated the safety, tolerability and pharmacokinetics of repirinast tablets in healthy Chinese volunteers. This was a phase I, open-label, randomized, single- and multiple-dose study. Subjects were assigned to receive a single dose of repirinast tablet at either 150, 300, or 450 mg, or multiple doses of 150 mg twice daily for 5 days. Plasma samples were analyzed with LC-MS/MS. Pharmacokinetic parameters of active metabolite MY-1250 (deesterified repirinast) were calculated using non-compartmental analysis with WinNonlin software. Statistical analysis was performed using SPSS software. All adverse events (AEs) were mild and of limited duration. No serious adverse event (SAE), death or withdrawal from the study was observed. In the single-dose study, Cmax was reached at about 0.75 hour, and the mean t1/2 was approximately 16.21 hours. Area under curve (AUC) and Cmax increased with dose escalation, but dose proportionality was not observed over the range of 150 to 450 mg. In the multiple-dose study, the steady-state was reached within 3 days with no accumulation. Repirinast tablet was well tolerated in healthy Chinese subjects.
Assuntos
Humanos , Masculino , Feminino , Adulto , Comprimidos/classificação , China/etnologia , Dose Repetida , Dose Única/métodos , Ensaio Clínico Controlado Aleatório , Antialérgicos/análise , Antialérgicos/farmacocinéticaRESUMO
Tryptanthrin and (E,Z)-3-(4-hydroxy-3,5-dimethoxybenzylidene)indolinone (indolinone) were recently isolated from Isatis tinctoria as potent anti-inflammatory and antiallergic alkaloids, and shown to inhibit COX-2, 5-LOX catalyzed leukotriene synthesis, and mast cell degranulation at low µM to nM concentrations. To assess their suitability for oral administration, we screened the compounds in an in vitro intestinal permeability assay using human colonic adenocarcinoma cells. For exact quantification of the compounds, validated UPLC-MS/MS methods were used. Tryptanthrin displayed high permeability (apparent permeability coefficient > 32.0 × 10(-6) cm/s) across the cell monolayer. The efflux ratio below 2 (< 1.12) and unchanged apparent permeability coefficient values in the presence of the P-glycoprotein inhibitor verapamil (50 µM) indicated that tryptanthrin was not involved in P-glycoprotein interactions. For indolinone, a low recovery was found in the human colon adenocarcinoma cell assay. High-resolution mass spectrometry pointed to extensive phase II metabolism of indolinone (sulfation and glucuronidation). Possible cardiotoxic liability of the compounds was assessed in vitro by measurement of an inhibitory effect on human ether-a-go-go-related gene tail currents in stably transfected HEK 293 cells using the patch clamp technique. Low human ether-a-go-go-related gene inhibition was found for tryptanthrin (IC50 > 10 µM) and indolinone (IC50 of 24.96 µM). The analysis of compounds using various in silico methods confirmed favorable pharmacokinetic properties, as well as a slight inhibition of the human ether-a-go-go-related gene potassium channel at micromolar concentrations.
Assuntos
Antialérgicos/farmacocinética , Anti-Inflamatórios não Esteroides/farmacocinética , Indóis/farmacocinética , Pirogalol/análogos & derivados , Quinazolinas/farmacocinética , Células CACO-2 , Permeabilidade da Membrana Celular , Cromatografia Líquida de Alta Pressão/métodos , Células HEK293 , Humanos , Absorção Intestinal , Isatis/química , Pirogalol/farmacocinética , Espectrometria de Massas em TandemRESUMO
The information about a marker compound's pharmacokinetics in herbal products including the characteristics of absorption, distribution, metabolism, excretion (ADME) is closely related to the efficacy/toxicity. Also dose range and administration route are critical factors to determine the ADME profiles. Since the supply of a sufficient amount of a marker compound in in vivo study is still difficult, pharmacokinetic investigations which overcome the limit of blood collection in mice are desirable. Thus, we have attempted to investigate concurrently the ADME and proposed metabolite identification of α-mangostin, a major constituent of mangosteen, Garcinia mangostana L, in mice with a wide dose range using an in vitro as well as in vivo automated micro-sampling system together. α-mangostin showed dose-proportional pharmacokinetics at intravenous doses of 5-20 mg/kg and oral doses of 10-100 mg/kg. The gastrointestinal absorption of α-mangostin was poor and the distribution of α-mangostin was relatively high in the liver, intestine, kidney, fat, and lung. α-mangostin was extensively metabolized in the liver and intestine. With regards to the formation of metabolites, the glucuronidated, bis-glucuronidated, dehydrogenated, hydrogenated, oxidized, and methylated α-mangostins were tentatively identified. We suggest that these dose-independent pharmacokinetic characteristics of α-mangostin in mice provide an important basis for preclinical applications of α-mangostin as well as mangosteen. In addition, these experimental methods can be applied to evaluate the pharmacokinetics of natural products in mice.
Assuntos
Antialérgicos/farmacocinética , Garcinia mangostana/química , Xantonas/farmacocinética , Administração Oral , Animais , Antialérgicos/administração & dosagem , Cromatografia Líquida , Avaliação Pré-Clínica de Medicamentos , Inativação Metabólica , Masculino , Camundongos Endogâmicos ICR , Espectrometria de Massas em Tandem , Distribuição Tecidual , Xantonas/administração & dosagemRESUMO
The aim of this study was to improve the oral absorption of loratadine, a pH-sensitive drug, by self-microemulsifying drug delivery systems (SMEDDSs). The optimal SMEDDS was analysed and evaluated after emulsification in distilled water with diameter of 26.57 ± 0.71 nm and zeta potential of -30.5 ± 4.5 mV. Dissolution experiments in vitro were carried out in different released media of pH values and the SMEDDS formulations were able to release loratadine completely in different media while market tablets just performed similarly in the media of pH 1.2. Furthermore, the oral bioavailability and the pharmacokinetic behaviour of loratadine formulations in vivo were studied after a single dose of 1 mg/kg loratadine in beagle dogs. The SMEDDS formulations displayed higher Cmax and AUC, approximately 9 and 5 times increase than those of market tablets (p < 0.01) respectively. These results demonstrated that SMEDDS formulations had significantly increased the oral absorption of loratadine in beagle dogs.
Assuntos
Antialérgicos , Sistemas de Liberação de Medicamentos/métodos , Liberação Controlada de Fármacos , Loratadina , Absorção pela Mucosa Oral , Animais , Antialérgicos/química , Antialérgicos/farmacocinética , Antialérgicos/farmacologia , Cães , Avaliação Pré-Clínica de Medicamentos , Emulsões , Concentração de Íons de Hidrogênio , Loratadina/química , Loratadina/farmacocinética , Loratadina/farmacologia , MasculinoRESUMO
PURPOSE: We examined the effect of a single apple juice intake on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese subjects. METHODS: In a randomized two phase, open-label crossover study, 14 subjects received 60 mg of racemic fexofenadine simultaneously with water or apple juice. For the uptake studies, oocytes expressing organic anion-transporting polypeptide 2B1 (OATP2B1) were incubated with 100 µM (R)- and (S)-fexofenadine in the presence or absence of 10 % apple juice. RESULTS: One-time ingestion of apple juice significantly decreased the area under the plasma concentration-time curve (AUC0-24) for (R)- and (S)-fexofenadine by 49 and 59 %, respectively, and prolonged the time to reach the maximum plasma concentration (t max) of both enantiomers (P < 0.001). Although apple juice greatly reduced the amount of (R)- and (S)-fexofenadine excretion into urine (Ae0-24) by 54 and 58 %, respectively, the renal clearances of both enantiomers were unchanged between the control and apple juice phases. For in vitro uptake studies, the uptake of both fexofenadine enantiomers into OATP2B1 complementary RNA (cRNA)-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine. In addition, apple juice significantly decreased the uptake of both enantiomers into OATP2B1 cRNA-injected oocytes. CONCLUSIONS: These results suggest that OATP2B1 plays an important role in the stereoselective pharmacokinetics of fexofenadine and that one-time apple juice ingestion probably inhibits intestinal OATP2B1-mediated transport of both enantiomers. In addition, this study demonstrates that the OATP2B1 inhibition effect does not require repeated ingestion or a large volume of apple juice.
Assuntos
Bebidas , Interações Alimento-Droga , Frutas , Malus , Transportadores de Ânions Orgânicos/metabolismo , Terfenadina/análogos & derivados , Adulto , Animais , Antialérgicos/sangue , Antialérgicos/química , Antialérgicos/farmacocinética , Antialérgicos/urina , Área Sob a Curva , Estudos Cross-Over , Ingestão de Alimentos , Feminino , Antagonistas não Sedativos dos Receptores H1 da Histamina/sangue , Antagonistas não Sedativos dos Receptores H1 da Histamina/química , Antagonistas não Sedativos dos Receptores H1 da Histamina/farmacocinética , Antagonistas não Sedativos dos Receptores H1 da Histamina/urina , Humanos , Absorção Intestinal , Masculino , Oócitos/metabolismo , Transportadores de Ânions Orgânicos/genética , RNA Complementar/genética , Estereoisomerismo , Terfenadina/sangue , Terfenadina/química , Terfenadina/farmacocinética , Terfenadina/urina , Xenopus laevis , Adulto JovemRESUMO
Dihomo-γ-linolenic acid (DGLA) is one of the polyunsaturated fatty acids, and is expected to show anti-allergic activity. We examined the effects of supplementation with DGLA-enriched oil (450 mg as free DGLA) for 4 weeks in healthy adults in a randomized controlled study. The DGLA composition in the total fatty acids of serum phospholipids increased from 2.0 to 3.4%, and returned to the initial level after a 4-week washout. No side effects or changes in blood biochemical parameters were observed. These results indicate that serum DGLA content can be safely increased by supplementation with 450 mg DGLA under these conditions.
Assuntos
Ácido 8,11,14-Eicosatrienoico/administração & dosagem , Antialérgicos/administração & dosagem , Ácido 8,11,14-Eicosatrienoico/química , Ácido 8,11,14-Eicosatrienoico/farmacocinética , Administração Oral , Adulto , Antialérgicos/química , Antialérgicos/farmacocinética , Ácidos Araquidônicos/sangue , Suplementos Nutricionais , Ácidos Docosa-Hexaenoicos/sangue , Ácido Eicosapentaenoico/sangue , Feminino , Humanos , Masculino , Fosfolipídeos/sangue , Adulto JovemRESUMO
INTRODUCTION: Olopatadine hydrochloride is an antihistamine and mast cell stabilizer available in three forms, including oral, intranasal and ocular preparations. Most of the practical applications focus on the use of olopatadine for the treatment of allergic rhinitis and conjunctivitis via intranasal and ocular routes. AREAS COVERED: This article was formed from a comprehensive literature search with information taken from meta-analyses, systematic reviews, treatment guidelines and clinical studies on children and adults. Articles that have been selected evaluate the use of intranasal and ocular antihistamines and their role in allergic rhinitis and conjunctivitis. EXPERT OPINION: Olopatadine is significantly more effective than placebos in alleviating the symptoms of allergic rhinitis and conjunctivitis. Olopatadine is a viable alternative and addition to the mainstay therapy of these conditions with intranasal steroids and oral antihistamines. The compliance of the patients would be improved if a once-per-day formulation of olopatadine was developed for intranasal application. The future treatments of allergic rhinitis will probably involve a combination of intranasal antihistamine and steroid because clinical trials have demonstrated an improved efficacy without a significant increase in adverse effects.
Assuntos
Antialérgicos/farmacocinética , Conjuntivite/tratamento farmacológico , Dibenzoxepinas/farmacocinética , Rinite/tratamento farmacológico , Administração Intranasal , Administração Oftálmica , Administração Oral , Antialérgicos/administração & dosagem , Ensaios Clínicos como Assunto , Dibenzoxepinas/administração & dosagem , Relação Dose-Resposta a Droga , Humanos , Metanálise como Assunto , Cloridrato de OlopatadinaRESUMO
The purpose of this study was to formulate drug-loaded polyelectrolyte matrices constituting blends of pectin, chitosan (CHT) and hydrolyzed polyacrylamide (HPAAm) for controlling the premature solvation of the polymers and modulating drug release. The model drug employed was the highly water-soluble antihistamine, diphenhydramine HCl (DPH). Polyelectrolyte complex formation was validated by infrared spectroscopy. Matrices were characterized by textural profiling, porositometry and SEM. Drug release studies were performed under simulated gastrointestinal conditions using USP apparatus 3. FTIR spectra revealed distinctive peaks indicating the presence of -COO(-) symmetrical stretching (1,425-1,390 cm(-1)) and -NH (3) (+) deformation (1,535 cm(-1)) with evidence of electrostatic interaction between the cationic CHT and anionic HPAAm corroborated by molecular mechanics simulations of the complexes. Pectin-HPAAm matrices showed electrostatic attraction due to residual -NH(2) and -COO(-) groups of HPAAm and pectin, respectively. Textural profiling demonstrated that CHT-HPAAm matrices were most resilient at 6.1% and pectin-CHT-HPAAm matrices were the least (3.9%). Matrix hardness and deformation energy followed similar behavior. Pectin-CHT-HPAAm and CHT-HPAAm matrices produced type IV isotherms with H3 hysteresis and mesopores (22.46 nm) while pectin-HPAAm matrices were atypical with hysteresis at a low P/P(0) and pore sizes of 5.15 nm and a large surface area. At t (2 h), no DPH was released from CHT-HPAAm matrices, whereas 28.2% and 82.2% was released from pectin-HPAAm and pectin-CHT-HPAAm matrices, respectively. At t (4 h), complete DPH release was achieved from pectin-CHT-HPAAm matrices in contrast to only 35% from CHT-HPAAm matrices. This revealed the release-modulating capability of each matrix signifying their applicability in controlled oral drug delivery applications.
Assuntos
Antialérgicos/química , Difenidramina/química , Sistemas de Liberação de Medicamentos , Resinas Acrílicas/química , Administração Oral , Antialérgicos/administração & dosagem , Antialérgicos/análise , Antialérgicos/farmacocinética , Quitosana/química , Simulação por Computador , Difenidramina/administração & dosagem , Difenidramina/farmacocinética , Formas de Dosagem , Portadores de Fármacos , Excipientes , Modelos Moleculares , Pectinas/química , Polímeros/química , Porosidade , Espectroscopia de Infravermelho com Transformada de Fourier , Propriedades de SuperfícieRESUMO
SCOPE: The purpose of this review is to examine published non-clinical literature on the antihistamine bepotastine besilate, including pharmacokinetic and pharmacologic properties. METHODS: Standard literature searches using diverse databases were used to find articles on bepotastine besilate published between 1997 and 2009. Articles primarily described non-clinical data utilized for the development of an oral formulation of bepotastine besilate and were published in Japanese. No publications of non-clinical data for an ophthalmic formulation were found in the database searches. FINDINGS: Bepotastine besilate is a second-generation antihistamine drug possessing selective histamine H(1) receptor antagonist activity. Bepotastine has negligible affinity for receptors associated with undesirable adverse effects, including histamine H(3), α(1)-, α(2)-, and ß-adrenergic, serotonin (5-HT(2)), muscarinic, and benzodiazepine receptors. Bepotastine possesses additional anti-allergic activity including stabilization of mast cell function, inhibition of eosinophilic infiltration, inhibition of IL-5 production, and inhibition of LTB(4) and LTD(4) activity. Bepotastine in vivo dose-dependently inhibited the acceleration of histamine-induced vascular permeability and inhibited homologous passive cutaneous anaphylaxis in guinea pig studies. In mouse models of itching, oral bepotastine inhibited the frequency and duration of scratching behavior. Multiple in vivo animal toxicology studies have demonstrated bepotastine to be safe with no significant effects on respiratory, circulatory, central nervous, digestive, or urinary systems. The concentration of bepotastine after intravenous administration of bepotastine besilate (3 mg/kg) in rats was lower in the brain than in plasma, predicting reduced sedation effects compared to older antihistamines. CONCLUSION: Non-clinical in vitro and in vivo studies have demonstrated bepotastine is a histamine H(1) receptor antagonist with favorable pharmacokinetic, pharmacologic, safety, and antihistamine properties as well as operating on other pathways leading to allergic inflammation beyond those directly involving the histamine H(1) receptor.
Assuntos
Piperidinas/efeitos adversos , Piperidinas/farmacologia , Piperidinas/farmacocinética , Piridinas/efeitos adversos , Piridinas/farmacologia , Piridinas/farmacocinética , Animais , Antialérgicos/efeitos adversos , Antialérgicos/farmacocinética , Antialérgicos/farmacologia , Antialérgicos/uso terapêutico , Conjuntivite Alérgica/tratamento farmacológico , Conjuntivite Alérgica/metabolismo , Conjuntivite Alérgica/patologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Antagonistas dos Receptores Histamínicos/efeitos adversos , Antagonistas dos Receptores Histamínicos/farmacocinética , Antagonistas dos Receptores Histamínicos/farmacologia , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Camundongos , Piperidinas/uso terapêutico , Prurido/tratamento farmacológico , Prurido/metabolismo , Prurido/patologia , Piridinas/uso terapêutico , RatosRESUMO
This study was designed to explore the pharmacokinetic interaction of Panax ginseng with fexofenadine in rats. Sprague-Dawley (SD) male rats were divided randomly into four groups: control oral and treatment oral dose groups (n = 6, respectively); control intravenous and treatment intravenous dose groups (n = 5, respectively). A single dose of fexofenadine (10 mg/kg for intravenous group rats and 100 mg/kg for oral dose group rats) was administered after 14 consecutive days of gastric gavage feeding of panax ginseng suspension (150 mg/kg/day) to treatment groups while the same volume of vehicle (1.6% ethanol) was administered as placebo to control groups. Blood samples were collected from 0 to 12 hours and levels of fexofenadine were measured by LC-MS/MS. Tissues were harvested to determine tissue/blood ratios. The pharmacokinetic parameters of fexofenadine were calculated using non-compartmental analysis. In the oral dose groups, (extravenous) panax ginseng decreased the area under the curve between 0-12 hours (AUC(0-12)) from 102490.7 +/- 25273.5 to 49933.3 +/- 12072.9 min*ng/ml (p < 0.005), decreased Cmax from 1102.0 +/- 116.6 to 274.3 +/- 180.6 ng/ml (p < 0.001), and significantly decreased ratios of brain to plasma concentration (B/P) (p < 0.05). In the intravenous groups, panax ginseng only reduced B/P ratios (p < 0.05). The mean bioavailability (F(ev)) of fexofenadine was decreased by 16.1% in the extravenous dose treatment group (p < 0.05). Long term administration of panax ginseng to rats might induce both intestinal and brain endothelium p-glycoprotein (p-gp) expression. In addition, long term use of panax ginseng reduced the bioavailability of concurrently administered fexofenadine.
Assuntos
Panax/química , Preparações de Plantas/farmacologia , Terfenadina/análogos & derivados , Animais , Antialérgicos/sangue , Antialérgicos/farmacocinética , Área Sob a Curva , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Masculino , Espectrometria de Massas , Taxa de Depuração Metabólica , Preparações de Plantas/administração & dosagem , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Terfenadina/sangue , Terfenadina/farmacocinética , Fatores de TempoRESUMO
In this article approaches to predict human pharmacokinetics (PK) are discussed and the capability of the exemplified methodologies to estimate individual PK parameters and therapeutic dose for a set of marketed oral drugs has been assessed. For a set of 63 drugs where the minimum efficacious concentration (MEC) and human PK were known, the clinical dose was shown to be well predicted or in some cases over-estimated using a simple one-compartment oral PK model. For a subset of these drugs, in vitro potency against the primary human targets was gathered, and compared to the observed MEC. When corrected for plasma protein binding, the MEC of the majority of compounds was < or=3 fold over the respective in vitro target potency value. A series of in vitro and in vivo experiments were conducted to predict the human PK parameters. Metabolic clearance was generally predicted well from human hepatocytes. Interestingly, for this compound set, allometry or glomerular filtration rate (GFR) ratio methods appeared to be applicable for renal CL even where CL(renal) > GFR. For approximately 90% of compounds studied, the predicted CL using in vitro-in vivo (IVIV) extrapolation together with a CL(renal) estimate, where appropriate, was within 2-fold of that observed clinically. Encouragingly volume of distribution at steady state (V(ss)) estimated in preclinical species (rat and dog) when corrected for plasma protein binding, predicted human V(ss) successfully on the majority of occasions--73% of compounds within 2-fold. In this laboratory, absorption estimated from oral rat PK studies was lower than the observed human absorption for most drugs, even when solubility and permeability appeared not to be limiting. Preliminary data indicate absorption in the dog may be more representative of human for compounds absorbed via the transcellular pathway. Using predicted PK and MEC values estimated from in vitro potency assays there was a good correlation between predicted and observed dose. This analysis suggests that for oral therapies, human PK parameters and clinical dose can be estimated from a consideration of data obtained from in vitro screens using human derived material and in vivo animal studies. The benefits and limitations of this holistic approach to PK and dose prediction within the drug discovery process are exemplified and discussed.
Assuntos
Antialérgicos/farmacocinética , Anti-Infecciosos/farmacocinética , Fármacos Cardiovasculares/farmacocinética , Fármacos do Sistema Nervoso Central/farmacocinética , Relação Dose-Resposta a Droga , Modelos Biológicos , Absorção , Administração Oral , Antialérgicos/administração & dosagem , Anti-Infecciosos/administração & dosagem , Fármacos Cardiovasculares/administração & dosagem , Fármacos do Sistema Nervoso Central/administração & dosagem , Humanos , Distribuição TecidualRESUMO
BACKGROUND: Intranasal and oral antihistamines are effective in treating allergic rhinitis. Studies comparing these routes of administration of an antihistamine regarding efficacy and pharmacokinetic profile are lacking. OBJECTIVE: To compare topical and oral routes of administration of cetirizine regarding efficacy, plasma exudation, and systemic drug levels in a repeated allergen challenge model of allergic rhinitis. METHODS: Oral cetirizine dihydrochloride, 10 mg once daily, and topical cetirizine dinitrate in a dose corresponding to 4.4 mg of the dihydrochloride salt twice daily were given to grass pollen-sensitive individuals for 12 days in a double-blind, placebo-controlled, crossover design. Timothy grass pollen allergen challenges were given once daily for 7 days using a nasal spray device. Nasal symptoms and peak inspiratory flow were recorded in the morning, 10 minutes after allergen challenge, and in the evening. The pharmacokinetics of the treatments was monitored in 8 patients. The remaining 28 patients were challenged topically with histamine 12 and 24 hours after the final topical and oral cetirizine doses, respectively. Nasal lavage levels of alpha2-macroglobulin were determined to evaluate histamine-induced mucosal plasma exudation. RESULTS: During the last 3 days of the repeated allergen challenge model, chronic symptoms were established. Both treatments reduced symptoms 10 minutes after allergen challenge (P < .001 vs placebo). Neither treatment reduced morning and evening symptoms or nasal peak inspiratory flow. Topical, but not oral, cetirizine reduced histamine-induced plasma exudation (P < .01 vs placebo) when systemic drug levels were similar in the 2 treatment regimens. CONCLUSIONS: Topical and oral cetirizine reduced acute nasal symptoms produced by allergen challenges in patients with established chronic symptoms. There were also antihistaminic effects of topical cetirizine not related to systemic drug levels.
Assuntos
Cetirizina/administração & dosagem , Cetirizina/farmacocinética , Rinite Alérgica Sazonal , Administração Oral , Adulto , Alérgenos , Antialérgicos/administração & dosagem , Antialérgicos/farmacocinética , Cetirizina/imunologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Antagonistas não Sedativos dos Receptores H1 da Histamina/administração & dosagem , Antagonistas não Sedativos dos Receptores H1 da Histamina/farmacocinética , Humanos , Masculino , Testes de Provocação Nasal , Pólen , Rinite Alérgica Sazonal/diagnóstico , Rinite Alérgica Sazonal/tratamento farmacológico , Rinite Alérgica Sazonal/imunologia , Resultado do TratamentoRESUMO
Herbal medicines are mixtures of more than one active ingredient. The multitude of pharmacologically active compounds obviously increases the likelihood of interactions taking place. Hence, the likelihood of herb-drug interactions is theoretically higher than drug-drug interactions, if only because synthetic drugs usually contain single chemical entities. Case reports and clinical studies have highlighted the existence of a number of clinically important interactions, although cause-and-effect relationships have not always been established. Herbs and drugs may interact either pharmacokinetically or pharmacodynamically. Through induction of cytochrome P450 enzymes and/or P-glycoprotein, some herbal products (e.g. St John's wort) have been shown to lower the plasma concentration (and/or the pharmacological effect) of a number of conventional drugs, including cyclosporine, indinavir, irinotecan, nevirapine, oral contraceptives and digoxin. The majority of such interactions involves medicines that require regular monitoring of blood levels. To date there is less evidence relating to the pharmacodynamic interaction. However, for many of the interactions discussed here, the understanding of the mechanisms involved is incomplete. Taking herbal agents may represent a potential risk to patients under conventional pharmacotherapy.
Assuntos
Interações Ervas-Drogas , Antialérgicos/farmacocinética , Antialérgicos/farmacologia , Antiasmáticos/farmacocinética , Antiasmáticos/farmacologia , Anti-Infecciosos/farmacocinética , Anti-Infecciosos/farmacologia , Fármacos Cardiovasculares/farmacocinética , Fármacos Cardiovasculares/farmacologia , Fármacos do Sistema Nervoso Central/farmacocinética , Fármacos do Sistema Nervoso Central/farmacologia , Ensaios Clínicos como Assunto , Anticoncepcionais Orais/farmacocinética , Anticoncepcionais Orais/farmacologia , Humanos , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/farmacologia , Imunossupressores/farmacocinética , Imunossupressores/farmacologiaAssuntos
Extratos Vegetais/efeitos adversos , Terfenadina/análogos & derivados , Antialérgicos/farmacocinética , Sistema Cardiovascular/efeitos dos fármacos , Ephedra/efeitos adversos , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Humanos , Hypericum/efeitos adversos , Farmacocinética , Terfenadina/farmacocinética , Estados Unidos , United States Food and Drug AdministrationRESUMO
BACKGROUND: St John's wort is a popular over-the-counter dietary supplement and herbal remedy that has been implicated in drug interactions with several substrates of P-glycoprotein. The effect of St John's wort on P-glycoprotein activity in vivo was examined with use of fexofenadine as selective probe drug. METHODS: A 3-period, open-label, fixed-schedule study design was used. Fexofenadine, 60 mg, was administered orally before administration of St John's wort, with a single dose of St John's wort (900 mg), and after 2 weeks of treatment with St John's wort (300 mg 3 times a day) to determine P-glycoprotein activity. RESULTS: A single dose of St John's wort significantly (P <.05) increased the maximum plasma concentration of fexofenadine by 45% and significantly (P <.05) decreased the oral clearance by 20%, with no change in half-life or renal clearance. Long-term administration of St John's wort did not cause a significant change in fexofenadine disposition relative to the untreated phase. Compared with the single-dose treatment phase, long-term St John's wort caused a significant 35% decrease (P <.05) in maximum plasma concentration and a significant 47% increase (P <.05) in fexofenadine oral clearance. CONCLUSIONS: A single dose of St John's wort resulted in a significant inhibition of intestinal P-glycoprotein. Long-term treatment with St John's wort reversed the changes in fexofenadine disposition observed with single-dose administration.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Hypericum/efeitos adversos , Terfenadina/análogos & derivados , Terfenadina/farmacocinética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/efeitos dos fármacos , Adulto , Antialérgicos/farmacocinética , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Humanos , Masculino , Valores de Referência , Terfenadina/sangueRESUMO
Desloratadine is a biologically active metabolite of the second-generation antihistamine loratadine. Desloratadine is a highly selective peripheral H1 receptor antagonist that is significantly more potent than loratadine. Results of in vitro and in vivo studies have suggested that desloratadine has anti-allergic effects that are unrelated to its ability to antagonise the effects of histamine. Desloratadine inhibits the expression of cell adhesion molecules, inhibits the generation and release of inflammatory mediators and cytokines, attenuates eosinophil chemotaxis, adhesion and superoxide generation. Studies in animals indicate that desloratadine does not cross the blood-brain barrier and therefore does not cause sedation and does not impair cognition or psychomotor performance. Desloratadine has an excellent overall safety profile. It has no effect on QRS and QTc intervals and does not cause arrhythmias. Desloratadine is not associated with any significant changes in gastrointestinal function. In clinical studies, oral desloratadine is rapidly absorbed and bioavailability is not affected by ingestion with food or grapefruit juice. The half-life of desloratadine in humans is 27 h; the linear kinetic profile is unaltered by race or gender. Desloratadine is not a substrate for P-glycoprotein or organic anion transport polypeptide and the drug does not appear to be metabolised to a significant extent by the cytochrome P450 CYP3A4 pathway. It therefore may be safely administered with ketoconazole, erythromycin, fluoxetine, or azithromycin. Clinically, desloratadine effectively controls both nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR), including nasal congestion. Desloratadine also provides significant relief of SAR symptoms in patients with co-existing asthma and is effective in the treatment of chronic idiopathic urticaria. Desloratadine improves quality of life and is well-tolerated.
Assuntos
Antialérgicos/farmacologia , Antialérgicos/uso terapêutico , Anti-Inflamatórios não Esteroides/farmacologia , Anti-Inflamatórios não Esteroides/uso terapêutico , Loratadina/farmacologia , Loratadina/uso terapêutico , Animais , Antialérgicos/farmacocinética , Anti-Inflamatórios não Esteroides/farmacocinética , Humanos , Loratadina/análogos & derivados , Loratadina/farmacocinéticaRESUMO
We conducted a population pharmacokinetic analysis of ephedrine, the main effective constituent of the two Kampo prescriptions, Sho-seiryu-to (Xiao-Qing-Long-Tang, Formula divinitatis caeruleae minor) and Kakkon-to (Ge-Gen-Tang, Formula puerariae), which are routinely used in the treatment of allergic rhinitis. Major pharmacokinetic differences were found in AUC(0-infinity), Cmax and the averages of the distribution volume between the two prescriptions. Using the pharmacokinetic results, we also conducted a simulation-based study comparing the pharmacokinetic profiles of ephedrine for the usual dosage regimen, a constant dose D three times a day before meals, and two alternative dosage regimens which are often used when patients' symptoms are not improved in the morning using the usual dosage regimen. The results suggested that one of the two alternative dosage regimens, two times D before breakfast and D in the afternoon, was the most effective from the pharmacokinetic viewpoint. This result was in accordance with our clinical experience.
Assuntos
Antialérgicos/farmacocinética , Efedrina/farmacocinética , Medicina Kampo , Adulto , Algoritmos , Antialérgicos/administração & dosagem , Antialérgicos/uso terapêutico , Área Sob a Curva , Simulação por Computador , Prescrições de Medicamentos , Efedrina/administração & dosagem , Efedrina/uso terapêutico , Humanos , Masculino , População , Rinite Alérgica Sazonal/tratamento farmacológicoRESUMO
OBJECTIVES: We evaluated the effect of orally administered tranilast, N-(3,4-dimethoxycinnamoyl) anthranilic acid, on histologic and histomorphometric changes after angioplasty or stent implantation in pig coronary arteries. BACKGROUND: Tranilast, which has antikeloid and antiallergic properties and therefore may modulate the fibrotic and inflammatory tissue responses to angioplasty and stenting, has been shown to inhibit angiographic restenosis in small clinical trials. However, its effect on histomorphometric changes in coronary arteries after angioplasty and stenting is unknown. METHODS: Following initial pharmacokinetic studies in two pigs to determine desirable plasma levels of orally administered tranilast, 36 crossbred juvenile pigs were randomized to placebo or tranilast before undergoing balloon angioplasty in both the left anterior descending and left circumflex plus stent implantation in the right coronary artery. Oral tranilast was administered at 3 g/day starting 3 days before coronary injury and continued for 28 days until euthanasia. Injured vessels were harvested and sections analyzed by computer-assisted microscopic planimetry. RESULTS: In balloon-injured vessels, tranilast was associated with a 37% reduction in neointimal area normalized to fracture length (0.47 +/- 0.01 vs. 0.74 +/- 0.03 mm; p < 0.001) and a 23% reduction in adventitial area normalized to vessel size (0.43 +/- 0.02 vs. 0.56 +/- 0.03; p = 0.003). In stented arteries, neointimal area normalized to injury score was 32% lower in the tranilast-treated group compared to control (1.94 +/- 0.17 vs. 2.86 +/- 0.29; p = 0.01). CONCLUSIONS: In pig coronary arteries, tranilast was associated with a reduction in neointima formation and adventitial reaction after balloon injury. In stented vessels, tranilast was associated with a reduction in neointima formation normalized to injury score.